Global Levothyroxine 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR062508351

Publication Date:

June 26, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Levothyroxine market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Levothyroxine is used to treat low thyroid activity and to treat or suppress different types of goiters.

Levothyroxine is a replacement for a hormone normally produced by your thyroid gland to regulate the body"s energy and metabolism. Levothyroxine is given when the thyroid does not produce enough of this hormone on its own.

Levothyroxine treats hypothyroidism (low thyroid hormone). It is also used to treat or prevent goiter (enlarged thyroid gland), which can be caused by hormone imbalances, radiation treatment, surgery, or cancer.
In United States, the key Levothyroxine manufacturers are Abbott Ltd, Alara Pharm (Sandoz), Forest (Actavis), Merck Serono, Piramal Healthcare, Mylan, KING PHARMS R AND D, Jerome Stevens etc. Top 3 companies occupied about 69% market share.
This report is a detailed and comprehensive analysis for global Levothyroxine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Levothyroxine market size and forecasts, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/Unit), 2020-2031
Global Levothyroxine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/Unit), 2020-2031
Global Levothyroxine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/Unit), 2020-2031
Global Levothyroxine market shares of main players, shipments in revenue ($ Million), sales quantity (K MT), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Levothyroxine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Levothyroxine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Ltd, Alara Pharm (Sandoz), Forest (Actavis), Merck Serono, Piramal Healthcare, Mylan, KING PHARMS R AND D, Jerome Stevens, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Levothyroxine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Slice in Solid
In Bottles for Injection
麻豆原创 segment by Application
Hospitals
Chemist's Shops
Others
Major players covered
Abbott Ltd
Alara Pharm (Sandoz)
Forest (Actavis)
Merck Serono
Piramal Healthcare
Mylan
KING PHARMS R AND D
Jerome Stevens
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Levothyroxine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Levothyroxine, with price, sales quantity, revenue, and global market share of Levothyroxine from 2020 to 2025.
Chapter 3, the Levothyroxine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Levothyroxine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Levothyroxine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Levothyroxine.
Chapter 14 and 15, to describe Levothyroxine sales channel, distributors, customers, research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Levothyroxine Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Slice in Solid
1.3.3 In Bottles for Injection
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Levothyroxine Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Chemist's Shops
1.4.4 Others
1.5 Global Levothyroxine 麻豆原创 Size & Forecast
1.5.1 Global Levothyroxine Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Levothyroxine Sales Quantity (2020-2031)
1.5.3 Global Levothyroxine Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Abbott Ltd
2.1.1 Abbott Ltd Details
2.1.2 Abbott Ltd Major Business
2.1.3 Abbott Ltd Levothyroxine Product and Services
2.1.4 Abbott Ltd Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Abbott Ltd Recent Developments/Updates
2.2 Alara Pharm (Sandoz)
2.2.1 Alara Pharm (Sandoz) Details
2.2.2 Alara Pharm (Sandoz) Major Business
2.2.3 Alara Pharm (Sandoz) Levothyroxine Product and Services
2.2.4 Alara Pharm (Sandoz) Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Alara Pharm (Sandoz) Recent Developments/Updates
2.3 Forest (Actavis)
2.3.1 Forest (Actavis) Details
2.3.2 Forest (Actavis) Major Business
2.3.3 Forest (Actavis) Levothyroxine Product and Services
2.3.4 Forest (Actavis) Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Forest (Actavis) Recent Developments/Updates
2.4 Merck Serono
2.4.1 Merck Serono Details
2.4.2 Merck Serono Major Business
2.4.3 Merck Serono Levothyroxine Product and Services
2.4.4 Merck Serono Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Merck Serono Recent Developments/Updates
2.5 Piramal Healthcare
2.5.1 Piramal Healthcare Details
2.5.2 Piramal Healthcare Major Business
2.5.3 Piramal Healthcare Levothyroxine Product and Services
2.5.4 Piramal Healthcare Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Piramal Healthcare Recent Developments/Updates
2.6 Mylan
2.6.1 Mylan Details
2.6.2 Mylan Major Business
2.6.3 Mylan Levothyroxine Product and Services
2.6.4 Mylan Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Mylan Recent Developments/Updates
2.7 KING PHARMS R AND D
2.7.1 KING PHARMS R AND D Details
2.7.2 KING PHARMS R AND D Major Business
2.7.3 KING PHARMS R AND D Levothyroxine Product and Services
2.7.4 KING PHARMS R AND D Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 KING PHARMS R AND D Recent Developments/Updates
2.8 Jerome Stevens
2.8.1 Jerome Stevens Details
2.8.2 Jerome Stevens Major Business
2.8.3 Jerome Stevens Levothyroxine Product and Services
2.8.4 Jerome Stevens Levothyroxine Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Jerome Stevens Recent Developments/Updates
3 Competitive Environment: Levothyroxine by Manufacturer
3.1 Global Levothyroxine Sales Quantity by Manufacturer (2020-2025)
3.2 Global Levothyroxine Revenue by Manufacturer (2020-2025)
3.3 Global Levothyroxine Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Levothyroxine by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Levothyroxine Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Levothyroxine Manufacturer 麻豆原创 Share in 2024
3.5 Levothyroxine 麻豆原创: Overall Company Footprint Analysis
3.5.1 Levothyroxine 麻豆原创: Region Footprint
3.5.2 Levothyroxine 麻豆原创: Company Product Type Footprint
3.5.3 Levothyroxine 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Levothyroxine 麻豆原创 Size by Region
4.1.1 Global Levothyroxine Sales Quantity by Region (2020-2031)
4.1.2 Global Levothyroxine Consumption Value by Region (2020-2031)
4.1.3 Global Levothyroxine Average Price by Region (2020-2031)
4.2 North America Levothyroxine Consumption Value (2020-2031)
4.3 Europe Levothyroxine Consumption Value (2020-2031)
4.4 Asia-Pacific Levothyroxine Consumption Value (2020-2031)
4.5 South America Levothyroxine Consumption Value (2020-2031)
4.6 Middle East & Africa Levothyroxine Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Levothyroxine Sales Quantity by Type (2020-2031)
5.2 Global Levothyroxine Consumption Value by Type (2020-2031)
5.3 Global Levothyroxine Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Levothyroxine Sales Quantity by Application (2020-2031)
6.2 Global Levothyroxine Consumption Value by Application (2020-2031)
6.3 Global Levothyroxine Average Price by Application (2020-2031)
7 North America
7.1 North America Levothyroxine Sales Quantity by Type (2020-2031)
7.2 North America Levothyroxine Sales Quantity by Application (2020-2031)
7.3 North America Levothyroxine 麻豆原创 Size by Country
7.3.1 North America Levothyroxine Sales Quantity by Country (2020-2031)
7.3.2 North America Levothyroxine Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Levothyroxine Sales Quantity by Type (2020-2031)
8.2 Europe Levothyroxine Sales Quantity by Application (2020-2031)
8.3 Europe Levothyroxine 麻豆原创 Size by Country
8.3.1 Europe Levothyroxine Sales Quantity by Country (2020-2031)
8.3.2 Europe Levothyroxine Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Levothyroxine Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Levothyroxine Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Levothyroxine 麻豆原创 Size by Region
9.3.1 Asia-Pacific Levothyroxine Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Levothyroxine Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Levothyroxine Sales Quantity by Type (2020-2031)
10.2 South America Levothyroxine Sales Quantity by Application (2020-2031)
10.3 South America Levothyroxine 麻豆原创 Size by Country
10.3.1 South America Levothyroxine Sales Quantity by Country (2020-2031)
10.3.2 South America Levothyroxine Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Levothyroxine Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Levothyroxine Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Levothyroxine 麻豆原创 Size by Country
11.3.1 Middle East & Africa Levothyroxine Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Levothyroxine Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Levothyroxine 麻豆原创 Drivers
12.2 Levothyroxine 麻豆原创 Restraints
12.3 Levothyroxine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Levothyroxine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Levothyroxine
13.3 Levothyroxine Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Levothyroxine Typical Distributors
14.3 Levothyroxine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Companies Mentioned:

Abbott Ltd
Alara Pharm (Sandoz)
Forest (Actavis)
Merck Serono
Piramal Healthcare
Mylan
KING PHARMS R AND D
Jerome Stevens

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.